Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Evolus Inc (NQ: EOLS )

9.700 +0.230 (+2.43%)
Streaming Delayed Price Updated: 11:30 AM EST, Dec 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Evolus Inc

< Previous 1 2 3 Next >
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
Evolus Reports Record Third Quarter 2023 Financial Results and Phase II Data for Extra-Strength 40U Formulation of Jeuveau®
From Evolus
Via Business Wire
“Extra-Strength” 40U Formulation of Jeuveau® Demonstrates Effects Lasting 26 Weeks in Phase II Data Presented at 2023 ASDS Annual Meeting
From Evolus
Via Business Wire
Evolus Inc. (NASDAQ: EOLS) Highlighted for Surprising Price Action
Via Investor Brand Network
Evolus to Participate in November Investor Conferences
From Evolus
Via Business Wire
Evolus to Report Third Quarter 2023 Results
From Evolus
Via Business Wire
Final Phase 2 Data Evaluating 40U Dose of PrabotulinumtoxinA-xvfs to be Presented at 2023 ASDS Annual Meeting
From Evolus
Via Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
Evolus to Participate in September Conferences
From Evolus
Via Business Wire
Evolus Announces Inducement Grants for New Chief Marketing Officer
From Evolus
Via Business Wire
Evolus Appoints Tomoko Yamagishi-Dressler as Chief Marketing Officer
From Evolus
Via Business Wire
Stonegate Capital Partners Announces Publishing of a Thematic Report - Undervalued Growth Pharma Companies Amidst Healthcare Sector Decline
Dallas, Texas--(Newsfile Corp. - August 8, 2023) - Stonegate is pleased to announce the... 
Via Newsfile
Evolus Unveils New Branding for Flagship Product Jeuveau® to Reflect Growing and Evolving Consumers
From Evolus
Via Business Wire
Evolus Reports Second Quarter 2023 Results and Provides Business Update
From Evolus
Via Business Wire
Evolus Raises Full-Year Revenue Guidance on Record Second Quarter 2023 Revenue
From Evolus
Via Business Wire
Evolus to Participate in Canaccord Genuity’s 43rd Annual Growth Conference
From Evolus, Inc.
Via Business Wire
Evolus to Report Second Quarter 2023 Results and Provide Business Update
From Evolus
Via Business Wire
Evolus Launches Nuceiva® (botulinum toxin type A) in Italy
From Evolus
Via Business Wire
Evolus Announces Successful Completion of Phase 2 Study Evaluating “Extra-Strength” Dose of Jeuveau ®
From Evolus
Via Business Wire
Evolus Reaches 1 Million Redemptions in its Evolus Rewards™ Patient Loyalty Program
From Evolus
Via Business Wire
Evolus Reports First Quarter 2023 Results and Provides Business Update
From Evolus
Via Business Wire
Evolus Announces Expansion into U.S. Dermal Filler Market with Evolysse™, a First-Generation Cold Technology HA by Symatese
From Evolus, Inc.
Via Business Wire
Evolus to Report First Quarter 2023 Results and Provide Business Update
From Evolus, Inc.
Via Business Wire
Evolus Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update
From Evolus
Via Business Wire
Evolus to Participate in the Barclays Global Healthcare Conference
From Evolus
Via Business Wire
Evolus Initiates Nuceiva® Launch in Germany and Austria
From Evolus, Inc.
Via Business Wire
Evolus to Report Fourth Quarter and Year End 2022 Results and Provide Business Update
From Evolus
Via Business Wire
Evolus Not Affected by Recent Korean Court Ruling
From Evolus
Via Business Wire
Evolus to Participate in the SVB Securities Global Biopharma Conference
From Evolus
Via Business Wire
"Extra-Strength" Formulation of Jeuveau® Demonstrates Effects Lasting 26 Weeks in Interim Phase II Data Results, Representing Prolonged 6-Month Performance
From Evolus
Via Business Wire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.